Brazil's Limited Legal Framework On Biosimilar Interchangeability Could Actually Help Sponsors
Executive Summary
Anvisa currently has no legislative authority to tell the Ministry of Health to refrain from providing biosimilar medications interchangeably, giving drugmakers an expanded opportunity to access Brazil's large patient population.
You may also be interested in...
Brazilian Notebook: Key Themes From BIO Latin America
Population size and favorable biosimilar policies highlight the opportunities for biotech in Brazil, but economic turmoil and other factors pose challenges.
Brazilian Notebook: Key Themes From BIO Latin America
Population size and favorable biosimilar policies highlight the opportunities for biotech in Brazil, but economic turmoil and other factors pose challenges.
Brazil: The Next Hot Spot For Biosimilar Substitution?
Biosimilars manufacturers could reach a wider patient population in Brazil if they can demonstrate interchangeably, as they do not face the potential barrier of discretion from states.